๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebo-controlled, crossover study

โœ Scribed by Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
110 KB
Volume
18
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a doubleโ€blind, placeboโ€controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Visit 1 or 2 and participated in the following two studies: (1) Finger tapping. Twentyโ€five PD patients used their index fingers to strike two keys 20 cm apart on a musical instrument digital interface (MIDI) keyboard. The slopes of the regression line of dwell time and movement time were used to assess the rate of fatigue development. (2) Force generation. Twelve PD patients contracted the wrist extensors maximally to obtain a baseline maximum voluntary contraction (BMVC) force. Then they repetitively contracted the wrist extensors at 50% of the BMVC for 7 seconds and rested for 3 seconds. An interval maximum voluntary contraction (IMVC) was measured every three repetitions. Fatigue was defined as an IMVC of less than 60% of the BMVC. The slope of the regression line of IMVC was used to assess the rate of force decline. These two studies were repeated 1 hour after carbidopa/levodopa (25/100) or placebo. Subjects filled out the Multidimensional Fatigue Inventory (MFI) at the beginning of the first visit. Results showed that the slope of dwell time decreased with levodopa but not with placebo (P = 0.004). The rate of force decline also decreased with levodopa but not with placebo (P = 0.01). The subscores in the dimension of physical fatigue in the MFI did not correlate with the rate changes in dwell time or the rate changes in force decline. We concluded that (1) levodopa improves physical fatigue in finger tapping and force generation, (2) physical fatigue in Parkinson's disease is at least partially related to dopamine deficiency, and (3) the MFI measures different aspects of physical fatigue compared with those measured by finger tapping and force generation. ยฉ 2003 Movement Disorder Society


๐Ÿ“œ SIMILAR VOLUMES


Levetiracetam in primary orthostatic tre
โœ Helge Hellriegel; Jan Raethjen; G. Deuschl; Jens Volkmann ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 314 KB ๐Ÿ‘ 1 views

## Abstract ## Background: In a doubleโ€blind crossover study we evaluated the antitremor effect of a 4โ€week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor. ## Methods: Twelve patients with orthostatic tremor participated in the study. Primary end point

Botulinum toxin type A for drooling in P
โœ Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Mari ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 65 KB

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gla

Acute effects of immediate and controlle
โœ Jaime Kulisevsky; Berta Pascual-Sedano; Manel Barbanoj; Alexandre Gironell; Javi ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 141 KB ๐Ÿ‘ 1 views

Mood fluctuations related to levodopa (LD) dosing are well-known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing-off) and to different pharmacokinetic profiles of oral L

Rotigotine transdermal patch in early Pa
โœ Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; An ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 167 KB

## Abstract Rotigotine is a new, nonโ€ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine,

Sarizotan as a treatment for dyskinesias
โœ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 117 KB ๐Ÿ‘ 1 views

## Abstract The objective of this study is to conduct a doseโ€finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5โ€HT~1A~ agonist properties and additio

Comparison of desipramine and citalopram
โœ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 118 KB ๐Ÿ‘ 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants